Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


BearingPoint Advises Wuhan On Billion-Dollar Biopharmaceutical Base

This article was originally published in PharmAsia News

Executive Summary

BearingPoint Management Consulting (Shanghai), subsidiary of BearingPoint, Inc., recently provided consulting services for Wuhan city on the establishment of its biopharmaceutical industrial base in the Donghu new technology development zone. This is a new milestone for BearingPoint as it represents the first customized biotechnology strategic planning project for China's leading high-tech zone. According to the ambitious plan, production value of the industry base is to reach RMB 14 billion, RMB 42 billion and RMB 130 billion by 2010, 2010-2015, and after 2020, respectively. Eventually, Donghu will make the biopharmaceutical industry its second production pillar worth hundreds of billion renminbi, after the electronics industry. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts